Richtlijn CVRM feb2013 - KNMP

Brown 2000
Brown 2003
Brown MJ, et al. Morbidity and mortality in patients randomized to double-blind treatment with a
long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study:
Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-372.
Brown MJ, Cruickshank JK, Dominiczak AF, MacGregor GA, Poulter NR, Russel GI, et al. Better blood
pressure control: how to combine drugs. J Hum Hypertens 2003; 17: 81-86.
Bruckert 2005 Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with
high-dose statin therapy in hyperlipidemic patients- the PRIMO study. Cardiovasc Drugs Ther
2005; 19: 403-414.
Bruckert 2011 Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P. Fibrates effect on
cardiovascular risk is greater in patients with high triglyceride levels or atherogenic
dyslipidemia profile: a systematic review and meta-analysis. Journal of Cardiovascular
Pharmacology.2011;57(2):267-272.
Brunetti 2010 Brunetti L, Hermes-Desantis ER. The role of colesevelam hydrochloride in
hypercholesterolemia and type 2 diabetes mellitus. Ann Pharmacother. 2010; 44(7-8):1196- 206.
Bijl 2010 Bijl D, 50 jaar diuretica bij de behandeling van hypertensie. Geneesmiddelenbulletin 2010; 44: 44-45.
Cannon 2004 Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus
moderate lipid lowering with statins after acute coronary syndromes. N Eng J Med 2004; 350: 1495-
1504.
Cannon 2010 Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in
patients with a planned invasive strategy for acute coronary syndromes (PLATO): a
randomised double-blind study. Lancet 2010 ; 375 (9711):283-93.
Cappuccio 2004 Cappuccio PL, Kerry SM, Forbes L, Donald A. Blood pressure control by home monitoring: metaanalysis
of randomized trials. BMJ 2004;329: 145.
Carlberg 2004 Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice Lancet 2004;
364: 1684-1689.
Casiglia 2002 Casiglia E, Mazza A, Tikhonoff et al. Weak effect of hypertension and other classic risk factors
in the elderly who have already paid their toll. J Hum Hypertension 2002; 16: 21-31
Caso 2007 Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms
in patients treated with statins. Am J Cardiol 2007; 99: 1409–1412.
Cayla 2012 Cayla G, Silvain J, O’Connor SA, Collet JP, Montalescot G. An evidence-based review of
current anti-platelet options for STEMI patients. Int J cardiol 2012 Jun 17 [epub ahead of
print]
CBG
Risico op cardiovasculaire en nierbijwerkingen aliskirenbevattende geneesmiddelen bij bepaalde
diabetespatiënten. Mededeling 6 jan 2012. www.cbg-meb.nl/CBG/nl/humane-geneesmiddelen
actueel/Risico_op_cardiovasculaire_en_nierbijwerkingen_aliskirenbevattende_geneesmiddelen_bij_bepaalde_diab/default.htm
CCT 2012 Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol
with statin therapy in people at low risk of vascular disease: meta-analysis of individual data
27 randomised trials. The Lancet 2012, 380 ( 9841): 581 – 590.
from
Chalres 2005 Chalres EC, Olson KL, Sandhoff BG, McCLure DL, Merenich JA. Evaluation of cases of severe
statin-related transaminitis within a large health maintenance organization. Am J Med 2005; 118:
618-24.
Chen 2010
Chen N, Zhou M, Yang M, Guo J, Zhu C, Yang J, Wang Y, Yang X, He L. Calcium channel blockers
versus other classes of drugs for hypertension. Cochrane Database of Systematic Reviews 2010, Issue
8. Art. No.: CD003654. DOI: 10.1002/14651858.CD003654.pub4
Chobanian 2003 Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee
on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report.
2003; 289: 2560-2572.
JAMA
85
CONCEPT